Combination chemotherapy with adriamycin, etoposide, and cyclophosphamide for small cell carcinoma of the lung. A study by the EORTC lung cancer working party (Belgium)
Open Access
- 1 July 1985
Abstract
The current study reports the results of Adriamycin (doxorubicin), etoposide, and cyclophosphamide (AVE) in small cell bronchogenic carcinoma. The overall rate of response was 82% in patients with limited disease and 66% in patients with extensive disease; complete remissions have been achieved in 20% of the patients with limited disease and in 7% of those with extensive disease. The median duration of survival was 14 months in patients with limited disease and 8.3 months in those with extensive disease. The results, and the analysis of literature, suggest that survival rather than response should be used to compare studies of chemotherapy in small cell bronchogenic carcinoma.This publication has 8 references indexed in Scilit:
- Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer.Journal of Clinical Oncology, 1983
- Cisplatin, adriamycin, and etoposide (cav) for remission induction of small-cell bronchogenic carcinoma. Evaluation of efficacy and toxicity and pilot study of a “late intensification” with autologous bone-marrow rescueCancer, 1982
- A phase I trial of continuous infusion VP16-213 (Etoposide)Cancer Chemotherapy and Pharmacology, 1982
- COMBINATION CHEMOTHERAPY FOR SMALL CELL-CARCINOMA OF THE LUNG - CONTINUOUS VERSUS ALTERNATING NON-CROSS-RESISTANT COMBINATIONS1982
- INTENSIVE INDUCTION CHEMOTHERAPY IN 54 PATIENTS WITH SMALL CELL-CARCINOMA OF THE LUNG1981
- Chemotherapy versus chemoimmunotherapy for small-cell undifferentiated carcinoma of the lungCancer, 1980